Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A

  • Post author:
  • Post category:uncategorized

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO.